Author
@BiotechCH BiotechCH
Biotech podcast/community hub delivering clinical-readout and deal-flow analysis with mixed sentiment
Aggregates and analyzes biotech/pharma news—clinical trial r
trader score
-1.16
hit rate
30%
mean α
-0.56%
signals 14d
7
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 20 scored bets: 30% hit rate, -0.56% mean alpha, trader score -1.16. Their last-14d mentions, direction-adjusted, have moved +1.2% since posting (mean over 6 mentions with price data).
Recent signals7receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-06-26 | SPRY | @BiotechCH | -0.40 | CVS Caremark deferred adding SPRY's Neffy to formulary until January 2027. | · | tweet ↗ |
| 2026-06-26 | ABBV | @BiotechCH | +0.05 | Discusses ABBV/APGE deal as evidence of high-quality, cheap China-sourced innovation. | +3.0% | tweet ↗ |
| 2026-06-26 | APGE | @BiotechCH | +0.45 | Discusses ABBV/APGE deal as evidence of high-quality, cheap China-sourced innovation. | +0.3% | tweet ↗ |
| 2026-06-26 | ABBV | @BiotechCH | -0.10 | ABBV announced plans to acquire APGE for $10.9B. | +3.0% | tweet ↗ |
| 2026-06-26 | APGE | @BiotechCH | +0.50 | ABBV announced plans to acquire APGE for $10.9B. | +0.3% | tweet ↗ |
| 2026-06-26 | XBI | @BiotechCH | +0.45 | Argues profitable biotech companies could draw generalists and benefit the sector. | +3.3% | tweet ↗ |
| 2026-06-26 | XBI | @BiotechCH | +0.55 | Says biotech fundamentals are coming together and it remains a great stock-pickers market. | +3.3% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.